Patents Assigned to Green Cross Corporation
  • (+)-3-HYDROXYMORPHINAN DERIVATIVES AS NEUROPROTECTANTS
    Publication number: 20120122848
    Abstract: A novel (+)-3-hydroxymorphinan derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating a neurodegenerative disease, are provided.
    Type: Application
    Filed: July 28, 2010
    Publication date: May 17, 2012
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Jong Yup Kim, Kwang-Seop Song, Jeongmin Kim, Kwang Woo Ahn, Yonggyu Kong
  • Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for Parkinson'S disease prevention or treatment
    Patent number: 8178551
    Abstract: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: May 15, 2012
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Jeongmin Kim, Myung Eun Jung, Jong Yup Kim, Kwang-Seop Song, Eun Jung Son, Suk Ho Lee, Ho Kyun Han, Min Ju Kim, MinWoo Lee
  • NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20120115881
    Abstract: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 10, 2012
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Hee Jeong Seo, Suk Youn Kang, Eun-Jung Park, Min Ju Kim, Suk Ho Lee, Jong yup Kim, Jeongmin Kim, Myung Eun Jung, Hyun Jung Kim, Mi-soon Kim, Ho kyun Han, Kwang Woo Ahn, Min Woo Lee, Ki-Nam Lee, Ae Nim Pae, Woo-Kyu Park
  • Method of Inhibiting Smooth Muscle Cell Proliferation by Using Reconstituted HDL
    Publication number: 20120108495
    Abstract: A method of inhibiting smooth muscle cell proliferation comprising administering to a subject a pharmaceutical composition including reconstituted HDL as an active ingredient.
    Type: Application
    Filed: October 25, 2011
    Publication date: May 3, 2012
    Applicants: GREEN CROSS CORPORATION, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Jeong Euy PARK, Bok Soo LEE, Ki Yong KIM
  • NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
    Publication number: 20120101051
    Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
    Type: Application
    Filed: June 18, 2010
    Publication date: April 26, 2012
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Suk Ho Lee, Hee Jeong Seo, Min Ju Kim, Suk Youn Kang, Jeongmin Kim, Sung-Han Lee, Myung Eun Jung, Eun Jung Son, Kwang-Seop Song, Mi-Soon Kim
  • SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
    Publication number: 20110178140
    Abstract: A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Application
    Filed: September 25, 2008
    Publication date: July 21, 2011
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Hee Jeong Seo, Min-Ah Kim, Jeongmin Kim, Sung-Han Lee, Myung Eun Jung, Mi-Soon Kim
  • ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS
    Publication number: 20110178091
    Abstract: The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.
    Type: Application
    Filed: September 23, 2009
    Publication date: July 21, 2011
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Suk Youn Kang, Eun-Jung Park, Kwang-Seop Song, Min Ju Kim, Hee Jeong Seo, Suk Ho Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
  • Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
    Patent number: 7875647
    Abstract: A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: January 25, 2011
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Jeong Min Kim, Chong-Hwan Jonathan Chang, Suk Ho Lee, Hee Jeong Seo, Suk Youn Kang, Kwang-Seop Song, Jong Yup Kim, Min-ah Kim, Sung-han Lee, Kwang-Woo Ahn, Myung Eun Jung, Ji-Hyun Park
  • USE OF HUMAN ANTIBODY CAPABLE OF NEUTRALIZING HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B VIRUS INFECTION
    Publication number: 20100260712
    Abstract: The present invention provides a use of a human antibody against a hepatitis B virus (HBV) surface antigen (HBsAg). The antibody exhibits an excellent HBV neutralizing ability, and thus, is useful for the prevention or treatment of the HBV infection or a disease caused thereby.
    Type: Application
    Filed: November 21, 2008
    Publication date: October 14, 2010
    Applicant: GREEN CROSS CORPORATION
    Inventors: Se-Ho Kim, Kwang-Won Hong, Yong-Nam Shin, Yong-Won Shin, Ki-Hwan Chang, Kyung-Hwan Ryoo, Jin-Seol Choi, Pan-Kyung Kim, Ki-Tae Bong, Dong-Hyuck Seo, Sun-Jeong Oh
  • ORALLY BIOAVAILABLE PRODUCTS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT
    Publication number: 20100113500
    Abstract: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.
    Type: Application
    Filed: March 7, 2008
    Publication date: May 6, 2010
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Jeongmin Kim, Myung Eun Jung, Jong Yup Kim, Kwang-Seop Song, Eun Jung Son, Suk Ho Lee, Ho Kyun Han, Min Ju Kim, MinWoo Lee
  • Azole Derivatives as Cannabinoid CB1 Receptor Antagonists
    Publication number: 20080262066
    Abstract: A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 23, 2008
    Applicant: Green Cross Corporation
    Inventors: Jinhwa LEE, Jeongmin Kim, Kwang-Seop Song, Min Ah Kim, Jong Yup Kim, Suk Ho Lee, Hee Jeong Seo, Sung-Han Lee, Myung Eun Jung, Kwang Woo Ahn, Eun Jung Son
  • HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
    Publication number: 20080207704
    Abstract: A heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing a heteroaryl-imidazole compound of formula (I), a pharmaceutical composition containing a heteroaryl-imidazole compound of formula (I), and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Application
    Filed: February 27, 2007
    Publication date: August 28, 2008
    Applicant: THE GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Jeongmin Kim, Jong Yup Kim, Hee Jeong Seo, Myung Eun Jung, Sung-Han Lee, Kwangwoo Ahn
  • Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists
    Publication number: 20080207705
    Abstract: A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Application
    Filed: February 27, 2008
    Publication date: August 28, 2008
    Applicant: Green Cross Corporation
    Inventors: Jinhwa LEE, Jeongmin Kim, Jong Yup Kim, Hee Jeong Seo, Myung Eun Jung, Sung-Han Lee, Kwangwoo Ahn, Suk Ho Lee
  • Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
    Publication number: 20080081815
    Abstract: A novel heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Application
    Filed: September 29, 2006
    Publication date: April 3, 2008
    Applicant: GREEN CROSS Corporation
    Inventors: Jinhwa Lee, Jeong Min Kim, Chong-Hwan Jonathan Chang, Suk Youn Kang, Hee Jeong Seo, Kwang-Seop Song, Sung-Han Lee, Kwang-Woo Ahn
  • Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists
    Publication number: 20080081812
    Abstract: A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Application
    Filed: September 28, 2007
    Publication date: April 3, 2008
    Applicant: Green Cross Corporation
    Inventors: Jinhwa LEE, Jeong Kim, Chong-Hwan Chang, Suk Lee, Hee Seo, Suk Kang, Kwang-Seop Song, Jong Kim, Min-ah Kim, Sung-han Lee, Kwang-Woo Ahn, Myung Eun Jung, Ji-Hyun Park
  • Humanized antibody specific for surface antigen pre-S1 of HBV and preparation method thereof
    Patent number: 7115723
    Abstract: The present invention relates to humanized antibodies specific for HBV surface antigen pre-S1, which show binding affinity similar to mouse monoclonal antibody and which show remarkably reduced immunogenicity since they have less mouse-derived amino acid residues. Thus, the humanized antibodies of the present invention may be useful for the prevention of HBV infection and for the treatment of hepatitis B.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: October 3, 2006
    Assignees: Korea Institute of Science and Technology, Korea Green Cross Corporation
    Inventors: Hyo Jeong Hong, Chun Jeih Ryu, Hyangsuk Hur
  • Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
    Patent number: 6887852
    Abstract: Disclosed is a lyophilized preparation of recombinant factor VIII used as a therapeutic preparation of hemophilia A. The lyophilized preparation of recombinant factor VIII is prepared by performing lyophilization using a mixture comprising 6 to 100 mM of L-arginine, 3.5 to 50 mM of L-isoleucine, and 10 to 100 mM of L-glutamic acid as a stabilizer for stabilizing the recombinant factor VIII which exhibits an unstable activity during lyophilization, rather than using human blood derived albumin.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: May 3, 2005
    Assignee: Korea Green Cross Corporation
    Inventors: Sang Hoon Paik, Yong Nam Shin, Jean Man Kim, Jae Wook Huh, Jung Sik Lee, Ki Sung Kwon, Ji Hyun Chun
  • Process of purifying angiogenesis inhibitors
    Patent number: 6770457
    Abstract: The present invention relates to process of purifying the angiogensis inhibitor proteins expressed in E. coli and to the use of recombinant kringle 1-3 (; greenstatin) purified by the above process as a angiogenesis inhibitor and an anticancer agent. Particularly, according to the process of purifying the protein, the angiogenesis inhibitor proteins overexpressed are solubilized, refolded, and purified as a pure and active form. The greenstatin purified by the process specifically suppresses endothelial cell proliferation, anaiogenesis, and the growth of lung cancer, skin cancer, and brain tumor. Therefore, the process of this invention is applicable to the mass-production of angiogenesis inhibitor proteins such as greenstatin which is useful for the treatment of glaucoma, retinopathy, and cancers.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: August 3, 2004
    Assignee: Korea Green Cross Corporation
    Inventors: Weon Kyoo You, Seung Ho So, Byung Cheul Ahn, Hyosil Lee, Soo-Il Jung, Young jo Kim, Jong Hyuk Lee, Yong-Kil Hong, Young Ae Joe, Soo-Ik Chang
  • Variant of C6 &bgr;-chemokine leukotactin-1(shLkn-1) with enhanced biological activity
    Patent number: 6692735
    Abstract: The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1, a process for preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and the inhibition of leukemia.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: February 17, 2004
    Assignees: Korea Green Cross Corporation, Mogam Biotechnology Research Institute
    Inventors: Byoung S. Kwon, Byung S. Youn, Soo-Il Chung, Doo-Hong Park, Seung Jae Baek, Eun-Kyoung Lee, Ju-Hyung Ahn, Kong-Ju Lee
  • Method of determining the enzymatic activity of the blood coagulation factor XIII using purified fibrin monomer as a substrate
    Patent number: 6406874
    Abstract: The present invention relates to a method of determining the enzymatic activity of blood coagulation factor XIII by using purified fibrin monomer as a substrate of this enzyme. The enzymatic activity is determined by detecting the degree of cross-linking of fibrin monomer formed by the blood coagulation factor XIII and the fibrin monomer free of blood coagulation factor XIII is obtained by washing the preparation with citric acid solution. The present method can be effectively used for the validation of the other enzymatic assay methods for the blood coagulation factor XIII as well as the studies for the characterization of the blood coagulation factor XIII.
    Type: Grant
    Filed: February 17, 1999
    Date of Patent: June 18, 2002
    Assignee: Korea Green Cross Corporation
    Inventors: Hee-Chul Kim, Jae-Wook Huh, Shin-Jae Chang, Jeung-Sik Lee, Soon-Kwan Chung, Hark-Mo Seong